Acepodia Biotech, Inc. announced clearance of the Investigational New Drug application (IND) by the U.S. Food and Drug Administration (FDA) for investigational product ACE2016,on February 2,2024,Taiwan time. Having received a Study May Proceed notification from the FDA, Acepodia expects to initiate a Phase 1 study in the coming months and to treat the first patient in the second half of 2024. Introduction to Clinical Trial Design: Trial Plan Name: A Phase 1 Multicenter Study Evaluating the Safety and Efficacy of ACE2016,an Allogeneic Anti-EGFR Conjugated Gamma Delta T cell (gdT) Therapy in Adult Subjects with Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR) Clinical Trial Population and Locations: Approximately 30 subjects are expected to be enrolled in the study, in the US.

Primary Objectives of the Trial: The study aims to evaluate the safety and tolerability of ACE2016. Classification of Trial Stages: Phase I, First in Human (FIH) Clinical Study. Trial Code: ACE2016-001 R&D New Drug Name or Code: ACE2016 Indication: A phase 1 study evaluating the safety, efficacy, and pharmacodynamics of ACE2016 in adult subjects with locally advanced or metastatic solid tumors expressing Epidermal Growth Factor Receptor (EGFR).

Planned development stages: Phase 1 ? 3 clinical studies, New Drug Application (NDA) submission Current development stage: Submission/Approval/Non-Approval/Results of Each Phase of Human Clinical Trials (Including Interim Analysis)/Occurrence of Other Significant Events Affecting New Drug Development: Received a Study May Proceed notification from the FDA to initiate a Phase 1 study. For those not approved by the competent authority for the intended purpose,or when the results of each phase of human clinical trials (including interim analysis) are not statistically significant or other significant events affecting new drug development occur, the risks the company faces and corresponding measures: Not applicable.

For those already approved by the competent authority for the intended purpose,or when the results of each phase of human clinical trials (including interim analysis) are statistically significant or other significant events affecting new drug development occur, the future operational direction: Not applicable. Cumulative R&D expenses incurred: Not disclosed at the moment due to concerns about future international collaboration negotiation information or product marketing strategy to protect investor interests Upcoming development plan: Expected Completion Time: Enrollment milestones are estimated to be completed at the end of 2026. The actual timeline will be continuously adjusted based on study progress.

Expected Obligations: Not applicable.